for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Glaukos Corp

GKOS.N

Latest Trade

41.69USD

Change

-1.76(-4.05%)

Volume

26,917

Today's Range

41.46

 - 

43.65

52 Week Range

23.31

 - 

76.01

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
43.45
Open
43.19
Volume
26,917
3M AVG Volume
14.52
Today's High
43.65
Today's Low
41.46
52 Week High
76.01
52 Week Low
23.31
Shares Out (MIL)
44.23
Market Cap (MIL)
1,921.81
Forward P/E
-22.71
Dividend (Yield %)
--

Next Event

Q3 2020 Glaukos Corp Earnings Release

Latest Developments

More

Glaukos Reports Q2 Non-GAAP Loss Per Share Of $0.61

Glaukos Corporation Announces Pricing Of Private Offering Of $250 Million Of 2.75% Convertible Senior Notes

Glaukos Says Intend To Offer $200 Million Of Convertible Senior Notes Due 2027 In Private Offering

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Glaukos Corp

Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm's canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream. It is developing three additional pipeline products: the iStent Inject, the iStent Supra and iDose. The iStent Inject includes two stents pre-loaded in an auto-injection inserter. The iStent Supra is designed to access an alternative drainage space within the eye. iDose is a drug delivery system that is designed to be implanted in the eye to continuously deliver therapeutic levels of medication for extended periods of time to lower intraocular pressure in glaucoma patients.

Industry

Medical Equipment & Supplies

Contact Info

229 Avenida Fabricante

SAN CLEMENTE, CA

92672-7531

United States

+1.949.3679600

http://www.glaukos.com/

Executive Leadership

William J. Link

Independent Chairman of the Board

Thomas William Burns

President, Chief Executive Officer, Director

Joseph E. Gilliam

Chief Financial Officer, Senior Vice President - Corporate Development

Chris M. Calcaterra

Chief Operating Officer

L. Jay Katz

Chief Medical Officer

Key Stats

2.82 mean rating - 11 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.2K

2018

0.2K

2019

0.2K

2020(E)

0.2K
EPS (USD)

2017

0.000

2018

-0.370

2019

0.370

2020(E)

-1.904
Price To Earnings (TTM)
--
Price To Sales (TTM)
8.06
Price To Book (MRQ)
2.99
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
9.25
LT Debt To Equity (MRQ)
9.25
Return on Investment (TTM)
-8.03
Return on Equity (TTM)
-7.40

Latest News

Latest News

BRIEF-Glaukos Corporation Announces Pricing Of Private Offering Of $250 Million Of 2.75% Convertible Senior Notes

* ORATION ANNOUNCES PRICING OF PRIVATE OFFERING OF $250 MILLION OF 2.75% CONVERTIBLE SENIOR NOTES

BRIEF-Glaukos Says Intend To Offer $200 Million Of Convertible Senior Notes Due 2027 In Private Offering

* GLAUKOS CORPORATION ANNOUNCES PROPOSED PRIVATE OFFERING OF $200 MILLION OF CONVERTIBLE SENIOR NOTES

BRIEF-Glaukos Corporation Announces First Quarter 2020 Financial Results

* Q1 SALES $55.3 MILLION VERSUS REFINITIV IBES ESTIMATE OF $58.5 MILLION

BRIEF-Glaukos Sees Q1 2020 Sales $55 Million To $55.3 Million

* PRELIMINARY AND UNAUDITED NET SALES FOR Q1 OF 2020 ARE EXPECTED TO BE IN RANGE OF $55.0 MILLION TO $55.3 MILLION

BRIEF-Glaukos Corp Withdraws Its Previously Announced Q1 And Annual Guidance For 2020

* GLAUKOS CORP - WITHDRAWING ITS PREVIOUSLY ANNOUNCED Q1 AND ANNUAL GUIDANCE FOR 2020 Source text for Eikon: Further company coverage:

BRIEF-Glaukos Corp Reports Q4 Earnings Per Share $0.84

* ANNOUNCES FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS

BRIEF-Glaukos Q1 Loss Per Share $0.08

* GLAUKOS CORP ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Glaukos Q4 Earnings Per Share $0.03

* ORATION ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Glaukos' Idose Travoprost Achieves Sustained IOP Reduction And Favorable Safety Profile In 12-Month Interim Cohort

* GLAUKOS CORPORATION’S IDOSE™ TRAVOPROST ACHIEVES SUSTAINED IOP REDUCTION AND FAVORABLE SAFETY PROFILE IN 12-MONTH INTERIM COHORT

BRIEF-Glaukos Submits IDE Application To FDA To Study iStent Infinite Trabecular Micro-Bypass System

* GLAUKOS SUBMITS IDE APPLICATION TO FDA TO STUDY ISTENT INFINITE™ TRABECULAR MICRO-BYPASS SYSTEM

BRIEF-Glaukos Corp posts Q3 earnings per share $0.04

* Glaukos Corporation announces third quarter 2017 financial results

BRIEF-James Flynn reports a 7.34 pct passive stake in Glaukos

* James E. Flynn reports a 7.34 Pct passive stake in Glaukos Corp as of Sept 14 - SEC filing Source text: [http://bit.ly/2xBLsij] Further company coverage:

BRIEF-Glaukos Corporation Q2 loss per share $0.10

* Glaukos Corporation announces second quarter 2017 financial results

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up